Cardiovascular Disorders Drug Development Pipeline Review, 2017

  • ID: 4191541
  • Report
  • Region: Global
  • 432 Pages
  • GBI Research
1 of 4
There are Over 1,200 Pipeline Products Within the CVD Therapy Area, Over 50% of these Products are Small Molecules

Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia of which accelerate the development of atherosclerotic plaques building up within blood vessels. As atheroma develops its causes stenosis of the blood vessels which can restrict blood flow to the body, brain or heart depending on its locale. It is also possible for the fibrous cap of the plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: Anti-hypertensives aim to lower blood pressure; anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range; and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of a current thrombi, they do this by either interrupting the coagulation cascade or inhibiting platelet aggregation, both of which inhibit blood from clotting.

There are over 1,200 pipeline products within the CVD therapy area. Over 50% of these products are small molecules however there is also diversification with regards to molecule types within the pipeline. In addition, the molecular targets in the pipeline are considerably diverse with a high frequency of products acting on targets related to lipid metabolism and those which act on elements of the coagulation cascade.

Among those pipeline drugs expected for imminent release to market there is a mixture of first-in-class products, typically anti-dyslipidemia drugs aiming to provide alternatives to statin therapy, and drugs belonging to currently popular classes such as PCSK9 inhibitors and direct factor Xa inhibitors.

The report provides comprehensive information on the pipeline development landscape for Hypertension, Dyslipidemia, Venous thromboembolism and Heart failure, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

  • Which companies are the most active within the pipeline for CVD?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1. Research Report Guidance

2. Executive Summary

3. Introduction

4. Cardiovascular Disorders Report Coverage

  • Hypertension Overview
  • Dyslipidemia Overview
  • Thromboembolism Overview
  • Heart Failure Overview

5. Therapeutics Development

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

6. Therapeutics under Development by Companies

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

7. Therapeutics under Investigation by Universities/Institutes

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

8. Pipeline Products Glance

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

9. Products under Development by Companies

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

10. Products under Investigation by Universities/Institutes

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

11. Companies Involved in Therapeutics Development

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

12. Therapeutics Assessment

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure
  • Dormant Projects
  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

13. Discontinued Products

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

14. Product Development Milestones

  • Hypertension
  • Dyslipidemia
  • Thromboembolism
  • Heart Failure

15. Appendix

  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation

List of Tables

  • Number of Products under Development for Hypertension
  • Number of Products under Development for Hypertension - Comparative Analysis
  • Number of Products under Development for Dyslipidemia
  • Number of Products under Development for Dyslipidemia - Comparative Analysis
  • Number of Products under Development for Thromboembolism
  • Number of Products under Development for Thromboembolism - Comparative Analysis
  • Number of Products under Development for Acute Heart Failure
  • Number of Products under Development for Congestive Heart Failure (Heart Failure)
  • Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis
  • Number of Products under Development for Chronic Heart Failure
  • Number of Products under Development for Chronic Heart Failure - Comparative Analysis
  • Number of Products under Development by Companies, Hypertension
  • Number of Products under Development by Companies, Dyslipidemia
  • Number of Products under Development by Companies, Thromboembolism
  • Number of Products under Development by Companies, Acute Heart Failure
  • Number of Products under Development by Companies, Congestive Heart Failure (Heart Failure)
  • Number of Products under Development by Companies, Chronic Heart Failure
  • Number of Products under Investigation by Universities/Institutes, Hypertension
  • Number of Products under Investigation by Universities/Institutes, Dyslipidemia
  • Number of Products under Investigation by Universities/Institutes, Thromboembolism
  • Number of Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure)
  • Number of Products under Investigation by Universities/Institutes, Chronic Heart Failure
  • Comparative Analysis by Late Stage Development, Hypertension
  • Comparative Analysis by Clinical Stage Development, Hypertension
  • Comparative Analysis by Early Stage Development, Hypertension
  • Comparative Analysis by Late Stage Development, Dyslipidemia
  • Comparative Analysis by Clinical Stage Development, Dyslipidemia
  • Comparative Analysis by Early Stage Development, Dyslipidemia
  • Comparative Analysis by Unknown Stage Development, Dyslipidemia
  • Comparative Analysis by Late Stage Development, Thromboembolism
  • Comparative Analysis by Clinical Stage Development, Thromboembolism
  • Comparative Analysis by Early Stage Development, Thromboembolism
  • Comparative Analysis by Late Stage Development, Acute Heart Failure
  • Comparative Analysis by Clinical Stage Development, Acute Heart Failure
  • Comparative Analysis by Early Stage Development, Acute Heart Failure
  • Comparative Analysis by Late Stage Development, Congestive Heart Failure (Heart Failure)
  • Comparative Analysis by Clinical Stage Development, Congestive Heart Failure (Heart Failure)
  • Comparative Analysis by Early Stage Development, Congestive Heart Failure (Heart Failure)
  • Comparative Analysis by Unknown Stage Development, Congestive Heart Failure (Heart Failure)
  • Comparative Analysis by Late Stage Development, Chronic Heart Failure
  • Comparative Analysis by Clinical Stage Development, Chronic Heart Failure
  • Comparative Analysis by Early Stage Development, Chronic Heart Failure
  • Products under Development by Companies, Hypertension
  • Products under Development by Companies, Dyslipidemia
  • Products under Development by Companies, Thromboembolism
  • Products under Development by Companies, Acute Heart Failure
  • Products under Development by Companies, Congestive Heart Failure (Heart Failure)
  • Products under Development by Companies, Chronic Heart Failure
  • Products under Investigation by Universities/Institutes, Hypertension
  • Products under Investigation by Universities/Institutes, Dyslipidemia
  • Products under Investigation by Universities/Institutes, Thromboembolism
  • Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure)
  • Products under Investigation by Universities/Institutes, Chronic Heart Failure
  • Hypertension - Pipeline by A1M Pharma AB
  • Hypertension - Pipeline by AbbVie Inc
  • Hypertension - Pipeline by Actelion Ltd
  • Hypertension - Pipeline by Afferent Pharmaceuticals Inc
  • Hypertension - Pipeline by Alnylam Pharmaceuticals Inc
  • Hypertension - Pipeline by Anacor Pharmaceuticals Inc
  • Hypertension - Pipeline by AnGes MG Inc
  • Hypertension - Pipeline by APT Therapeutics Inc
  • Hypertension - Pipeline by Arena Pharmaceuticals Inc
  • Hypertension - Pipeline by Ascendis Pharma A/S
  • Hypertension - Pipeline by Asklepion Pharmaceuticals LLC
  • Hypertension - Pipeline by AVEO Pharmaceuticals Inc
  • Hypertension - Pipeline by Bayer AG
  • Hypertension - Pipeline by Bial - Portela & Ca SA
  • Hypertension - Pipeline by Biolab Farmaceutica Ltda
  • Hypertension - Pipeline by BioRestorative Therapies Inc
  • Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd
  • Hypertension - Pipeline by Cellceutix Corp
  • Hypertension - Pipeline by Celsion Corp
  • Hypertension - Pipeline by Celtaxsys Inc
  • Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp
  • Hypertension - Pipeline by CJ HealthCare Corp
  • Hypertension - Pipeline by Complexa Inc
  • Hypertension - Pipeline by Conatus Pharmaceuticals Inc
  • Hypertension - Pipeline by Corion Biotech Srl
  • Hypertension - Pipeline by Cumberland Pharmaceuticals Inc
  • Hypertension - Pipeline by Cytokinetics Inc
  • Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd
  • Hypertension - Pipeline by Daiichi Sankyo Company Ltd
  • Hypertension - Pipeline by DiaMedica Inc
  • Hypertension - Pipeline by Eli Lilly and Company
  • Hypertension - Pipeline by Esperion Therapeutics Inc
  • Hypertension - Pipeline by F. Hoffmann-La Roche Ltd
  • Hypertension - Pipeline by Ferring International Center SA
  • Hypertension - Pipeline by Galectin Therapeutics Inc
  • Hypertension - Pipeline by Genextra Spa
  • Hypertension - Pipeline by Gilead Sciences Inc
  • Hypertension - Pipeline by GlaxoSmithKline Plc
  • Hypertension - Pipeline by Glenveigh Medical LLC
  • Hypertension - Pipeline by HanAll Biopharma Co Ltd
  • Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd
  • Hypertension - Pipeline by HitGen LTD
  • Hypertension - Pipeline by Innopharmax Inc
  • Hypertension - Pipeline by Insmed Inc
  • Hypertension - Pipeline by INVENT Pharmaceuticals Inc
  • Hypertension - Pipeline by Ionis Pharmaceuticals Inc
  • Hypertension - Pipeline by Ironwood Pharmaceuticals Inc
  • Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd
  • Hypertension - Pipeline by Johnson & Johnson
  • Hypertension - Pipeline by JW Pharmaceutical Corp
  • Hypertension - Pipeline by Kowa Company Ltd
  • Hypertension - Pipeline by Leading BioSciences Inc
  • Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd
  • Hypertension - Pipeline by Les Laboratoires Servier SAS
  • Hypertension - Pipeline by LFB SA
  • Hypertension - Pipeline by LG Life Science LTD
  • Hypertension - Pipeline by LinXis BV
  • Hypertension - Pipeline by Liquidia Technologies Inc
  • Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd
  • Hypertension - Pipeline by MannKind Corp
  • Hypertension - Pipeline by Mast Therapeutics Inc
  • Hypertension - Pipeline by Merck & Co Inc
  • Hypertension - Pipeline by Mezzion Pharma Co Ltd
  • Hypertension - Pipeline by miRagen Therapeutics Inc
  • Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp
  • Hypertension - Pipeline by Morphogen-IX Ltd
  • Hypertension - Pipeline by Neurim Pharmaceuticals Ltd
  • Hypertension - Pipeline by Nippon Kayaku Co Ltd
  • Hypertension - Pipeline by Nippon Shinyaku Co Ltd
  • Hypertension - Pipeline by Novartis AG
  • Hypertension - Pipeline by Noxamet Ltd
  • Hypertension - Pipeline by Omeros Corp
  • Hypertension - Pipeline by Peloton Therapeutics Inc
  • Hypertension - Pipeline by Pfizer Inc
  • Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc
  • Hypertension - Pipeline by Pluristem Therapeutics Inc
  • Hypertension - Pipeline by Polyphor Ltd
  • Hypertension - Pipeline by Proteo Inc
  • Hypertension - Pipeline by Pulmokine Inc
  • Hypertension - Pipeline by Quantum Genomics SA
  • Hypertension - Pipeline by Reata Pharmaceuticals Inc

List of Figures

  • Number of Products under Development for Hypertension
  • Number of Products under Development for Hypertension - Comparative Analysis
  • Number of Products under Development for Dyslipidemia
  • Number of Products under Development for Dyslipidemia - Comparative Analysis
  • Number of Products under Development for Thromboembolism
  • Number of Products under Development for Thromboembolism - Comparative Analysis
  • Number of Products under Development for Acute Heart Failure
  • Number of Products under Development for Congestive Heart Failure (Heart Failure)
  • Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis
  • Number of Products under Development for Chronic Heart Failure
  • Number of Products under Development for Chronic Heart Failure - Comparative Analysis
  • Number of Products under Development by Companies, Hypertension
  • Number of Products under Development by Companies, Dyslipidemia
  • Number of Products under Development by Companies, Thromboembolism
  • Number of Products under Development by Companies, Acute Heart Failure
  • Number of Products under Development by Companies, Congestive Heart Failure (Heart Failure)
  • Number of Products under Development by Companies, Chronic Heart Failure
  • Number of Products under Investigation by Universities/Institutes, Hypertension
  • Number of Products under Investigation by Universities/Institutes, Dyslipidemia
  • Number of Products under Investigation by Universities/Institutes, Congestive Heart Failure (Heart Failure)
  • Comparative Analysis by Late Stage Development, Hypertension
  • Comparative Analysis by Clinical Stage Development, Hypertension
  • Comparative Analysis by Early Stage Products, Hypertension
  • Comparative Analysis by Late Stage Development, Dyslipidemia
  • Comparative Analysis by Clinical Stage Development, Dyslipidemia
  • Comparative Analysis by Early Stage Products, Dyslipidemia
  • Comparative Analysis by Late Stage Development, Thromboembolism
  • Comparative Analysis by Clinical Stage Development, Thromboembolism
  • Comparative Analysis by Early Stage Products, Thromboembolism
  • Comparative Analysis by Clinical Stage Development, Acute Heart Failure
  • Comparative Analysis by Late Stage Development, Congestive Heart Failure (Heart Failure)
  • Comparative Analysis by Clinical Stage Development, Congestive Heart Failure (Heart Failure)
  • Comparative Analysis by Early Stage Products, Congestive Heart Failure (Heart Failure)
  • Comparative Analysis by Clinical Stage Development, Chronic Heart Failure
  • Comparative Analysis by Early Stage Products, Chronic Heart Failure
  • Assessment by Monotherapy Products, Hypertension
  • Assessment by Combination Products, Hypertension
  • Number of Products by Top 10 Targets, Hypertension
  • Number of Products by Stage and Top 10 Targets, Hypertension
  • Number of Products by Top 10 Mechanism of Actions, Hypertension
  • Number of Products by Stage and Top 10 Mechanism of Actions, Hypertension
  • Number of Products by Top 10 Routes of Administration, Hypertension
  • Number of Products by Stage and Top 10 Routes of Administration, Hypertension
  • Number of Products by Top 10 Molecule Types, Hypertension
  • Number of Products by Stage and Top 10 Molecule Types, Hypertension
  • Assessment by Monotherapy Products, Dyslipidemia
  • Assessment by Combination Products, Dyslipidemia
  • Number of Products by Top 10 Targets, Dyslipidemia
  • Number of Products by Stage and Top 10 Targets, Dyslipidemia
  • Number of Products by Top 10 Mechanism of Actions, Dyslipidemia
  • Number of Products by Stage and Top 10 Mechanism of Actions, Dyslipidemia
  • Number of Products by Routes of Administration, Dyslipidemia
  • Number of Products by Stage and Routes of Administration, Dyslipidemia
  • Number of Products by Molecule Types, Dyslipidemia
  • Number of Products by Stage and Molecule Types, Dyslipidemia
  • Assessment by Monotherapy Products, Thromboembolism
  • Number of Products by Targets, Thromboembolism
  • Number of Products by Stage and Targets, Thromboembolism
  • Number of Products by Mechanism of Actions, Thromboembolism
  • Number of Products by Stage and Mechanism of Actions, Thromboembolism
  • Number of Products by Routes of Administration, Thromboembolism
  • Number of Products by Stage and Routes of Administration, Thromboembolism
  • Number of Products by Molecule Types, Thromboembolism
  • Number of Products by Stage and Molecule Types, Thromboembolism
  • Assessment by Monotherapy Products, Acute Heart Failure
  • Number of Products by Top 10 Targets, Acute Heart Failure
  • Number of Products by Stage and Top 10 Targets, Acute Heart Failure
  • Number of Products by Top 10 Mechanism of Actions, Acute Heart Failure
  • Number of Products by Stage and Top 10 Mechanism of Actions, Acute Heart Failure
  • Number of Products by Routes of Administration, Acute Heart Failure
  • Number of Products by Stage and Routes of Administration, Acute Heart Failure
  • Number of Products by Molecule Types, Acute Heart Failure
  • Number of Products by Stage and Molecule Types, Acute Heart Failure
  • Assessment by Monotherapy Products, Congestive Heart Failure (Heart Failure)
  • Number of Products by Top 10 Targets, Congestive Heart Failure (Heart Failure)
  • Number of Products by Stage and Top 10 Targets, Congestive Heart Failure (Heart Failure)
  • Number of Products by Top 10 Mechanism of Actions, Congestive Heart Failure (Heart Failure)
  • Number of Products by Stage and Top 10 Mechanism of Actions, Congestive Heart Failure (Heart Failure)
  • Number of Products by Top 10 Routes of Administration, Congestive Heart Failure (Heart Failure)
  • Number of Products by Stage and Top 10 Routes of Administration, Congestive Heart Failure (Heart Failure)
  • Number of Products by Top 10 Molecule Types, Congestive Heart Failure (Heart Failure)
  • Number of Products by Stage and Top 10 Molecule Types, Congestive Heart Failure (Heart Failure)
  • Assessment by Monotherapy Products, Chronic Heart Failure
  • Number of Products by Top 10 Targets, Chronic Heart Failure
  • Number of Products by Stage and Top 10 Targets, Chronic Heart Failure
  • Number of Products by Top 10 Mechanism of Actions, Chronic Heart Failure
  • Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Heart Failure
  • Number of Products by Routes of Administration, Chronic Heart Failure
  • Number of Products by Stage and Routes of Administration, Chronic Heart Failure
  • Number of Products by Molecule Types, Chronic Heart Failure
  • Number of Products by Stage and Molecule Types, Chronic Heart Failure
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • A1M Pharma AB
  • APT Therapeutics Inc
  • AVEO Pharmaceuticals Inc
  • AbbVie Inc
  • Actelion Ltd
  • Afferent Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • AnGes MG Inc
  • Anacor Pharmaceuticals Inc
  • Arena Pharmaceuticals Inc
  • Ascendis Pharma A/S
  • Asklepion Pharmaceuticals LLC
  • Bayer AG
  • Bial - Portela & Ca SA
  • BioRestorative Therapies Inc
  • Biolab Farmaceutica Ltda
  • Boryung Pharmaceutical Co Ltd
  • CJ HealthCare Corp
  • Cellceutix Corp
  • Celsion Corp
  • Celtaxsys Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Complexa Inc
  • Conatus Pharmaceuticals Inc
  • Corion Biotech Srl
  • Cumberland Pharmaceuticals Inc
  • Cytokinetics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Company Ltd
  • DiaMedica Inc
  • Eli Lilly and Company
  • Esperion Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Ferring International Center SA
  • Galectin Therapeutics Inc
  • Genextra Spa
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenveigh Medical LLC
  • HanAll Biopharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • HitGen LTD
  • INVENT Pharmaceuticals Inc
  • Innopharmax Inc
  • Insmed Inc
  • Ionis Pharmaceuticals Inc
  • Ironwood Pharmaceuticals Inc
  • JW Pharmaceutical Corp
  • Jeil Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Kowa Company Ltd
  • LFB SA
  • LG Life Science LTD
  • Leading BioSciences Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Les Laboratoires Servier SAS
  • LinXis BV
  • Liquidia Technologies Inc
  • Lotus Pharmaceutical Co Ltd
  • MannKind Corp
  • Mast Therapeutics Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • miRagen Therapeutics Inc
  • Morphogen-IX Ltd
  • Neurim Pharmaceuticals Ltd
  • Nippon Kayaku Co Ltd
  • Nippon Shinyaku Co Ltd
  • Novartis AG
  • Noxamet Ltd
  • Omeros Corp
  • Peloton Therapeutics Inc
  • Pfizer Inc
  • PhaseBio Pharmaceuticals Inc
  • Pluristem Therapeutics Inc
  • Polyphor Ltd
  • Proteo Inc
  • Pulmokine Inc
  • Quantum Genomics SA
  • Reata Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll